Welcome to the 6th Gene Therapy Analytical Development Summit Europe
Join the community advancing analytics & QC from Pre-IND/IMPD to BLA
The 6th Gene Therapy Analytical Development Summit Europe was the premier platform for advancing gene therapy analytics, empowering you to overcome challenges and fast-track therapies through IND/IMPD filings, clinical trials, and regulatory approvals.
With the gene therapy field progressing toward late-stage development, and hurdles like Rocket Pharma’s KRESLADI rejection spotlighting critical gaps in CMC data, this summit provided timely, industry-focused insights tailored for the European market.
24+ expert speakers tackled characterisation, stability studies, contamination risks, and comparability across vectors and diseases.
The summit also fostered networking with biotech, pharma, the MHRA and British Pharmacopoeia, to share innovative solutions, and shape the future of gene therapy. This was the only European event dedicated to driving analytical precision, QC strategy and delivering safe, effective therapies to patients worldwide.
World-Class Speaker Faculty in 2025 Included:
"2024 had a strong focus on analytics, rather than being too diverse, such as on antibodies or other ADCs. Bringing people together to discuss hot topics in detail and share insights and challenges was extremely beneficial."
2024 Attendee, Principal Scientist, Freeline Therapeutics
Companies Attending in 2025 Included
"This smaller, more intimate setting really facilitated the discussions. There is a very good representation of experts in specific fields with a well thought out agenda."
2024 Attendee, Chief Operating Officer, Coave Therapeutics
Our Partners in 2025
